First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes
This month, our newest publication is the full report of the Eversense study results. Eversense is the very nifty sensor that is implanted subcutaneously and provides continuous glucose monitoring to your phone for 6 months. Our results were in teenagers – the first pediatric study – and were the first to verify the full 180-day lifespan of this generation of the device, and the first in a Pediatric population. The results were presented by Dr. Alex Abitbol and Dr. Ronnie Aronson at the EASD and ADA sessions last year.
